High-risk HPV (hrHPV) Prevalence and Effectiveness of HPV Vaccination Under Different Vaccination Scenarios.

<p>The prevalence refers to hrHPV prevalence among females 10–70 years of age. Base-case vaccination scenario: 80% vaccination coverage among women; wide range of type-specific protection (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072088#pone-0072088-t001" target="_blank">Table 1</a>); 20 years duration of vaccine induced protection waning on average in the next 20 years. Lower cross-protection: vaccine efficacy 50% against type 31, and 0% against other non-vaccine types; Shorter protection: 10 years duration of vaccine induced protection waning on average in the next 10 years; G/B the coverage of vaccination for girls/boys. High-risk HPV infection includes both transient and persistent infections (Pers.inf.). The effectiveness of HPV -vaccination is defined as a relative reduction in the corresponding prevalence (post-vaccination vs pre-vaccination era).